anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Fetoscopic closure of spina bifida using heated and humidified carbon dioxide gas (hhCO2) has been associated with lower maternal morbidity compared with open closure. Fetal cardiovascular changes during these surgical interventions are poorly defined. Our objective was to compare fetal bradycardia (defined as fetal heart rate (FHR) < 110 bpm for 10 min) and changes in umbilical artery (UA) Doppler parameters during open vs fetoscopic closure.
METHODS: This was a prospective cohort study of 22 open and 46 fetoscopic consecutive in-utero closures conducted between 2019 and 2023. Both cohorts had similar preoperative counseling and clinical management. FHR and UA Doppler velocimetry were obtained systematically during preoperative assessment, every 5 min during the intraoperative period, and during the postoperative assessment. FHR, UA pulsatility index (PI) and UA end-diastolic flow (EDF) were segmented into hourly periods during surgery, and the lowest values were averaged for analysis. Umbilical vein maximum velocity was measured in the fetoscopic cohort. At each timepoint at which FHR was recorded, maternal heart rate and systolic and diastolic blood pressure were measured.
RESULTS: Fetal bradycardia occurred in 4/22 (18.2%) cases of open closure and 21/46 (45.7%) cases of fetoscopic closure (P = 0.03). FHR decreased gradually in both cohorts after administration of general anesthesia and decreased further during surgery. FHR was significantly lower during hour 2 of surgery in the fetoscopic-repair cohort compared with the open-repair cohort. The change in FHR from baseline in the final stage of fetal surgery was significantly more pronounced in the fetoscopic-repair cohort compared with the open-repair cohort (mean, -32.4 (95% CI, -35.7 to -29.1) bpm vs -23.5 (95% CI, -28.1 to -18.8) bpm; P = 0.002). Abnormal UA-EDF (defined as absent or reversed EDF) occurred in 3/22 (13.6%) cases in the open-repair cohort and 23/46 (50.0%) cases in the fetoscopic-repair cohort (P = 0.004). There were no differences in UA-EDF or UA-PI between closure techniques at the individual stages of assessment.
CONCLUSIONS: We observed a decrease in FHR and abnormalities in UA Doppler parameters during both open and fetoscopic spina bifida closure. Fetal bradycardia was more prominent during fetoscopic closure following hhCO2 insufflation, but FHR recovered after cessation of hhCO2. Changes in FHR and UA Doppler parameters during in-utero spina bifida closure were transient, no cases required emergency delivery and no fetoscopic closure was converted to open closure. These observations should inform algorithms for the perioperative management of fetal bradycardia associated with in-utero spina bifida closure. © 2024 International Society of Ultrasound in Obstetrics and Gynecology.
The invention discloses a fusion toxicant having the function of selectively killing new blood vessel endothelial cells of tumors and an application thereof. The fusion toxicant is a fusion protein which is prepared in the way that the amido ends of ribosome inactivating proteins RIP30 of balsam pear seeds are connected with VEGF121 through connecting peptides. As a carrier, VEGF121 can internalize and bond the fusion toxicant to blood vessel endothelial cell nutrilite receptors F1k1/KDR in a specific way before the fusion toxicant enters blood vessel endothelial cells and plays a role as a toxicant to kill new blood vessel endothelial cells of tumors, to destroy the new blood vessels of tumor tissues and cut off the blood supply of tumors, thus inhibiting tumors. In addition, the expression conditions of the fusion toxicant are simple; the fusion toxicant is purified easily and can be produced in large scale. Accordingly, the fusion toxicant can be used as an active ingredient for preparing antineoplastic drugs. The fusion protein can play an important role in the medical and biological pharmacy field.
PURPOSE:To provide the titled agent containing glycyrrhizin or glycyrrhezic acid as an active component, having excellent activity to lower testosterone level in blood, useful for the remedy of hypomenorrhea, sterility and hypertrichosis, etc., and having high safety. CONSTITUTION:The objective agent contains glycyrrhizin of formula I or glycyrrhezic acid of formula II as an active component. The compound of formula I or formula II suppresses the production of testosterone in interstitial cell extremely remarkably. The action is higher in glycyrrhizin than in glycyrrhezic acid. The effective dose of glycyrrhizin is 30-50mg daily for intravenous injection and 150-250mg daily for oral administration, and that of glycyrrhezic acid is 15-35mg daily for intravenous injection and 100-200mg daily for oral administration. The agent is useful for the remedy of hypomenorrhea, sterility, hypertrichosis, acne vulgaris, etc.
This study is being done to compare the rate of ovulation when women receive two subdermal implant contraception devices containing the hormone etonogestrel (instead of only one device) while taking the HIV drug efavirenz. The etonogestrel implant is a device that is inserted under the skin on the upper arm and releases a small amount of drug into the body every day over a long period of time to prevent pregnancy for 3 years. A total of 72 non-pregnant women in Uganda, who agree to use the copper intrauterine device throughout the study, will participate in this study. Half will be assigned by chance to use one implant and half will be assigned to use two implants at the entry visit. After the entry visit to place the implant, visits will be scheduled 1 week, 4 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 21 weeks, 22, weeks, 23 weeks, 24 weeks, 36 weeks, 45 weeks, 46 weeks, 47 weeks, and 48 weeks after the implant(s) were placed. The rate of ovulation (determined by weekly endogenous progesterone concentrations in the blood during months 3, 6, and 12) will be compared between women that receive two 68 mg etonogestrel implants compared to one 68 mg etonogestrel implant in combination with efavirenz-based antiretroviral therapy. Cervical mucus quality (from cervical mucus samples collected weekly at months 3, 6, and 12), the blood concentration of etonogestrel (from blood samples collected at day 3 and weeks 1, 4, 12, 24, 36, 48) and efavirenz (from blood samples collected at enrollment and weeks 4, 12, 24, 36, 48, and the number of adverse events deemed related to etonogestrel implant use through 48 weeks will also be compared between the one- and two-implant study arms.
Atrial fibrillation (AF) is the most common sustained cardiac dysrhythmia encountered in practice. It is currently estimated that AF affects approximately 2% of the general population; however, the true prevalence of AF is likely to be at least 3%-4% when asymptomatic AF is considered. For clinically apparent AF, the investigations and management are relatively well established. The identification of minimally symptomatic patients is challenging, and furthermore, the optimal management is less certain. Although there is some debate about the ideal treatment pathway for asymptomatic AF, in most cases, the investigations and comprehensive management follow the same recommendations as clinically apparent AF. In contrast, beyond risk factor optimisation, the ideal management of subclinical or device-detected AF remains undefined. The purpose of the current review is to discuss the assessment and management of asymptomatic AF.
Patients receive newly-developed educational materials about breast reconstruction and attend a standard of care consultation visit with their plastic surgeon to discuss options for breast reconstruction surgery. At the end of the consultation visit, patients complete questionnaires about decision-making and psychological well-being. Within 4-6 weeks and 3-6 months after beginning the reconstruction process, patients also complete questionnaires about satisfaction with their breasts, body image, and psychological well-being, and undergo 2D and 3D imaging of the torso.
FIELD: chemistry; biochemistry. ^ SUBSTANCE: invention relates to biotechnology and the DNA version related to adult hypolactasia. The substance of invention includes a nucleic acid molecule containing the 5'-end part of the intestinal digestive lactase-phlorizin hydrolase (LPH) gene which participates or serves as an indicator of adult hypolactasia. The said nucleic acid molecule is selected from a group consisting of: (a) nucleic acid molecules having the SEQ ID N0:1 sequence or containing it, where the SEQ ID NO:1 sequence and (b) nucleic acid molecules having the SEQ ID NO:2 sequence or containing it, (c) nucleic acid molecules consisting of at least 20 nucleotides whose complementary strand is hybridised in strict conditions with the nucleic acid molecule at point (a) or (b), where the said polynucleotide/or nucleic acid molecule contains a cytosine residue in a position corresponding to position -13910 in the 5'-direction from the LPH gene; and (d) nucleic acid molecules consisting of at least 20 nucleotides whose complementary strand is hybridised in strict conditions with the nucleic acid molecule at point (a) or (b), where the said polynucleotide/nucleic acid molecule contains a guanine residue in a position corresponding to position -22018 in the 5'-direction from the LPH gene. ^ EFFECT: design of a method of testing presence or predisposition to adult hypolactasia, which is based on SNP analysis, contained in the said nucleic acid molecule. ^ 65 cl, 7 ex, 8 tbl, 9 dwg
<P>PROBLEM TO BE SOLVED: To provide a new contact lens capable of safely providing a contact lens whose expiration date is preliminarily determined to a user without imposing any excess load on the user or a oculist and to provide its diagnosing system.  <P>SOLUTION: A user 18 is made to share a periodical membership fee, and the contact lens is provided through a preliminarily selected member store 14 to the user 18. That is, it is possible to provide new contact lens for exchange to the member user 18 who continues to pay the periodical membership fee without requiring any special procedure when the user 18 visits the member store 14. Also, the user 18 is able to receive periodical medical examination at the member store 14 at receiving the provision of the contact lens. Then, a providing main body 10 of the contact lens manages various information including the personal information of the user, and constructs a database 24.  <P>COPYRIGHT: (C)2003,JPO
PURPOSE: To evaluate the immediate effect of the inspiratory exercise with a booster and a respiratory exerciser on the voice of women without vocal complaints.
METHODS: 25 women with no vocal complaints, between 18 and 34 years old, with a score of 1 on the Vocal Disorder Screening Index (ITDV) participated. Data collection was performed before and after performing the inspiratory exercise and consisted of recording the sustained vowel /a/, connected speech and maximum phonatory times (MPT) of vowels, fricative phonemes and counting numbers. In the auditory-perceptual judgment, the Vocal Deviation Scale (VSD) was used to verify the general degree of vocal deviation. Acoustic evaluation was performed using the PRAAT software and the parameters fundamental frequency (f0), jitter, shimmer, harmonium-to-noise ratio (HNR), Cepstral Peak Prominence Smoothed (CPPS), Acoustic Voice Quality Index (AVQI) and Acoustic Breathiness Index (ABI). To measure the aerodynamic measurements, the time of each emission was extracted in the Audacity program. Data were statistically analyzed using the Statistica for Windows software and normality was tested using the Shapiro-Wilk test. To compare the results, Student's and Wilcoxon's t tests were applied, adopting a significance level of 5%.
RESULTS: There were no significant differences between the results of the JPA and the acoustic measures, in the pre and post inspiratory exercise moments. As for the aerodynamic measures, it was possible to observe a significant increase in the value of the TMF /s/ (p=0.008).
CONCLUSION: There was no change in vocal quality after the inspiratory exercise with stimulator and respiratory exerciser, but an increase in the MPT of the phoneme /s/ was observed after the exercise.
<P>PROBLEM TO BE SOLVED: To provide a method for producing an extract of Ipomoea batatas sp. containing a glycolipid from the Ipomoea batatas sp., or a sphingoglycolipid in order to obtain a daily ingestible brain ganglioside substitute of livestock safe for human bodies without a risk such as BSE (bovine spongiform encephalopathy), to provide a neurocyte activator containing the glycolipid or sphingoglycolipid derived from the Ipomoea batatas sp. and to provide a healthy food using the same.  <P>SOLUTION: The extract of the Ipomoea batatas sp. is obtained as follows. The Ipomoea batatas sp. is dipped in a polar solvent to thereby extract the glycolipid or sphingoglycolipid into a polar solvent. The resultant dipping liquid is then concentrated to afford the extract of the Ipomoea batatas sp. Effects of activating actions on the neurocytes are confirmed by using an established neuroblast.  <P>COPYRIGHT: (C)2007,JPO&INPIT
A beverage and method of preparing a beverage comprising various combinations of flower essences designed for human consumption to treat emotional, mental and physical illnesses while providing hydration. In one illustrative embodiment of the method herein, a beverage is first formed by mixing a flower essence tincture with a diluent. A preservative flavoring and sweetener may also be added to the mixture. The beverage is then added to an empty container to form a filled container and then sealed to form a beverage product. The filled container may be sealed by, without limitation, applying a vacuum to the beverage therein, and/or capping an opening of the filled container. The capping may include applying a cap to the container, such as plastic or metallic cap. The container may be a plastic, glass or metallic bottle.
PURPOSE:To provide the title product capable of enhancing NK cell activity and early improving immunological competence after operation, leading to preventing complication (infection), thus useful for stimulating the immunity of patients depressed in immunological competence after operation. CONSTITUTION:The objective product having above-mentioned effects, containing, as the essential ingredient, an ester wherein phosphoric acid-based substance or glyceride with omega-3 or omega-6 fatty acid is contained as constituent. When the content of the former fatty acid is 1 to 8 (pref. 3-7) times that of the latter fatty acid, both the acids will mutually act antagonistically, resulting in early manifestation of NK activity after operation. The present product can be administered as an activity enhancer for NK cells by addition thereof to established perintestinal nutrients, and its daily dosage per adult being 0.1-50 (pref. 0.3-40)g in terms of omega-3 fatty acid.
Risk Summary 

There are no data regarding the presence of vonoprazan in human milk, the effects on the breastfed infant, or the effects on milk production. Vonoprazan and its metabolites are present in rat milk. Liver injury occurred in offspring from pregnant and lactating rats administered oral vonoprazan at AUC exposures approximately equal to and greater than the MRHD (see Data). When a drug is present in animal milk, it is likely that the drug will be present in human milk. Because of the potential risk of adverse liver effects shown in animal studies with vonoprazan, advise patients not to breastfeed during treatment with VOQUEZNA.

Data

Animal Data

In a PPND study in rats, in which the dams were administered oral vonoprazan during gestation and through lactation at up to 22-times the MRHD (based on AUC comparison), liver discoloration occurred in offspring from the high dose group [see Use in Specific Populations (8.1)].

Liver discoloration associated with necrosis, fibrosis, and hemorrhage in the offspring of dosed rats was also seen in dose range-finding studies and follow-up, mechanistic studies including offspring in lactation only studies. These effects were reported in pups on LD 4 at doses from 3 to 100 mg/kg/day (approximately 0.2- to 22-fold the MRHD based on AUC values extrapolated from the PPND study) and on LD 14 at doses from 10 to 100 mg/kg/day dose groups (approximately 1- to 22-fold the MRHD based on an extrapolated AUC comparisons). In mechanistic studies, liver effects were observed in offspring treated only during lactation but not in offspring from animals only treated during gestation. In some of these studies, this finding was associated with increased offspring stomach weights that was reversed along with liver discoloration by concomitant treatment with a gastrointestinal prokinetic agent.
OBJECTIVE: Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by abnormal myeloid blast expansion. Recent studies have demonstrated that circular RNAs play a role in AML pathogenesis. In this study, we aimed to investigate the clinical significance of circ_0012152 in AML and elucidate its underlying molecular mechanism in the pathogenesis of this condition.
METHODS: Circ_0012152 expression was detected by quantitative real-time polymerase chain reaction in samples obtained from 247 patients with AML and 40 healthy controls. A systematic analysis of clinical characteristics and prognostic factors was also conducted. Cell growth was assessed using the Cell Counting Kit-8 (CCK-8) assay, and apoptosis and cell cycle progression were evaluated by flow cytometry. Moreover, RNA pull-down was performed to identify target microRNAs, and transcriptome RNA sequencing and bioinformatics analyses were utilized to identify downstream mRNA targets.
RESULTS: Circ_0012152 was significantly upregulated in samples from patients with AML and served as an independent adverse prognostic factor for overall survival (OS) (hazard ratio: 2.357; 95% confidence interval 1.258-4.415). The circ_0012152 knockdown reduced cell growth, increased apoptosis, and inhibited cell cycle progression in AML cell lines. RNA pull-down and sequencing identified miR-652-3p as a target microRNA of circ_0012152. Cell growth inhibition by circ_0012152 knockdown was significantly relieved by miR-652-3p inhibitors. We suggested that miR-652-3p targeted SOX4, as the decrease in SOX4 expression resulting from circ_0012152 knockdown was upregulated by miR-652-3p inhibitors in AML cells.
CONCLUSION: Circ_0012152 is an independent poor prognostic factor for OS in AML, and it promotes AML cell growth by upregulating SOX4 through miR-652-3p.
BACKGROUND: Fibrotic scar formation is a critical pathological change impacting tissue reconstruction and functional recovery after ischemic stroke. The regulatory mechanisms behind fibrotic scarring in the central nervous system (CNS) remain largely unknown. While macrophages are known to play a role in fibrotic scar formation in peripheral tissues, the involvement of microglia, the resident immune cells of the CNS, in CNS fibrosis requires further exploration. The Sonic Hedgehog (Shh) signaling pathway, pivotal in embryonic development and tissue regeneration, is also crucial in modulating fibrosis in peripheral tissues. However, the impact and regulatory mechanisms of Shh on fibrotic scar formation post-ischemic stroke have not been thoroughly investigated.
METHODS: This study explores whether Shh can regulate fibrotic scar formation post-ischemic stroke and its underlying mechanisms through in vivo and in vitro manipulation of Shh expression.
RESULTS: Our results showed that Shh expression was upregulated in the serum of acute ischemic stroke patients, as well as in the serum, CSF, and ischemic regions of MCAO/R mice. Moreover, the upregulation of Shh expression was positively correlated with fibrotic scar formation and M2 microglial polarization. Shh knockdown inhibited fibrotic scar formation and M2 microglial polarization while aggravating neurological deficits in MCAO/R mice. In vitro, adenoviral knockdown or Smoothened Agonist (SAG) activation of Shh expression in BV2 cells following OGD/R regulated their polarization and influenced the expression of TGFβ1 and PDGFA, subsequently affecting fibroblast activation.
CONCLUSION: These results suggest that Shh regulates M2 microglial polarization and fibrotic scar formation after cerebral ischemia.
The invention comprises an active polypeptide composition characterized by being electrophoretically homogeneous, having a molecular weight between 6600 and 8000, producing growth in stabilized adult female rats, producing a tibial epiphyseal response in hypophysectomized female rats, accelerating the utilization of glucose by muscle, accelerating the oxidation of C14 glucose by adipose tissue located in the intestinal section and also accelerating the rate of C14 amino acid incorporation into the protein of muscle and into the protein of epididymal adipose tissue. The polypeptide is prepared from purified preparations of animal or human growth hormones or from impure preparations containing these, e.g. animal pituitary glands or the acetone-insoluble portion of animal pituitary glands.  The growth hormone preparation is subjected to acid hydrolysis at a pH of 1.5 to 2.5 preferably in an aqueous medium containing ethanol, n-butanol, toluene and water in the proportions of 4 : 0.4 : 0.4 : 1 by volume.  The insoluble portion is recovered from the extraction solvent and dried, extracted with 0.1 M acetic acid, and the extract so formed is filtered through an ultrafilter.  The ultrafiltrate is passed through a cation-exchange resin on the hydrogen cycle, washed with water to recover unabsorbed material, and the aqueous solution treated with an ethanol-ether mixture to precipitate the active polypeptide.  The dried precipitate is dissolved in water, the pH adjusted to 8.5 with ammonia, the resultant solution filtered and the polypeptide precipitated by the addition of a mixture of ethanol and ether.
Study subjects are patients who are diagnosed with an unruptured saccular intracranial aneurysm and planned for elective surgical treatment of intracranial aneurysms. Prior the planned surgery, all study subjects will undergo PET-imaging of the brain with 18F-FDG- and 68Ga-DOTANOC-tracers targeting glucose metabolism and somatostatin receptors in inflammatory cells. After PET-imaging, samples for histopathological examination from the intracranial aneurysm sac will be collected during the surgery from every study subject. Blood samples are collected prior to aneurysm operation from the routine pre-operative laboratory tests. Cerebrospinal fluid samples are collected during the surgical procedure from the surgical site. From blood samples we will evaluate expression of 20 different circulating microRNAs (miRNA) and the level of tumor necrosis factor-1, interleukin 1 beta, vascular endothelial growth factor, and evaluate correlations between miRNA expression and SUVmax in PET-imaging and miRNA and aneurysm histological findings.

Correlation between inflammatory findings in histological studies and PET-imaging will be evaluated (correlation of SUVmax to aneurysm histological findings).
Participants are admitted for two days and two nights to an inpatient clinical research center for performance of study procedures. On Day 1, two hyperinsulinemic hypoglycemic (50 mg/dl) clamps are performed - an AM clamp from about 9 to 11 am and a PM clamp from about 1 to 3 pm.. Modified Oxford procedures are performed in duplicate at five time points -- before the AM clamp, during the AM clamp, before the PM clamp, during the PM clamp, and the morning of Day 2 (about 16 hrs after completion of the the PM clamp). The Modified Oxford procedure involves the sequential intravenous administration of nitroprusside and phenylephrine with assessment of blood pressure and heart rate by finapress. Baroreflex sensitivity is the relationship of changes in heart rate to changes in blood pressure. .